Biagio Ricciuti: Resistance mechanisms in insertion-mutant NSCLC
Biagio Ricciuti shared on X:
“Resistance mechanisms to EGFR TKIs in EGFR ex 20 insertion-mutant NSCLC:
- 9 patients treated with mobocertinib
- EGFR amp (focal or broad N=6)
- EGFR mutations (N=3, including C797S)
- aneuploidy (WGD and chr 7p gain).“
Authors: Siyeon Park, Seongyeol Park, Tae Min Kim, Soyeon Kim, Jaemoon Koh, Joonoh Lim, Kijong Yi, Boram Yi, Young Seok Ju, Miso Kim, Bhumsuk Keam, Jung Sun Kim, Yoon Kyung Jeon, Dong-Wan Kim, Young Tae Kim, Dae Seog Heo
Source: Biagio Ricciuti/X
Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023